Abstract
Between 2018 and 2022, we conducted whole-genome sequencing and phylogenomic analysis on 173 Vibrio cholerae bacteria (172 V. cholerae O1 and 1 V. cholerae non-O1/non-O139 isolates) from cholera patients across four provinces in the Democratic Republic of Congo (North-Kivu, South-Kivu, Tanganyika, and Kasai Oriental). All V. cholerae O1 isolates were classified into the AFR10d and AFR10e sublineages of AFR10 lineage, originating from the third wave of the seventh El Tor cholera pandemic (7PET). Compared to the strains analysed between 2014 and 2017, we observed only limited genetic changes in the core genome of both sublineages. However, AFR10e expanded across the four provinces, whereas AFR10d appeared to become extinct by the end of 2020. The V. cholerae isolates from 2022 exhibited significant rearrangement in the CTX prophage and associated phage satellites. Notably, this included the tandem repeat of a novel environmental satellite phage RS1 downstream the ctxB toxin gene of the CTX-Φ-3 prophage on the large chromosome, and two tandemly arrayed copies of the pre-CTX-Φ prophage precursor on the small chromosome. In conclusion, while the core genome of V. cholerae O1 AFR10d and AFR10e sublineages showed minimal changes, significant alterations in the content and organisation of elements associated with the CTX-Φ and pre-CTX prophages were identified in AFR10e V. cholerae O1 isolated in 2022.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Belgian Cooperation Agency of the ARES (Académie de Recherche et d'Enseignement Supérieur) under grant COOP-CONV-20-022. The funder had no role in the study design, collection, analysis and interpretation of data, preparation of the manuscript, or the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols received approval from the Ethical Review Board (ERB) of the Institut supérieur des techniques médicales de Bukavu, Democratic Republic of the Congo (ethical approval ISTM-BUKAVU/CRPS/CIES/ML/0016/2023). The ERB granted a waiver of informed consent, determining that the study complied with international guidelines applicable to research during severe outbreaks. To protect confidentiality, samples were analysed anonymously.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data produced in the present work are contained in the manuscript
